Director, Structural Biology

What if… you could join an organization that creates, resources, and builds life sciences companies that invent breakthrough technologies to transform human health and sustainability?

Flagship Pioneering's venture creation engine has conceived and created companies such as Moderna Therapeutics (NASDAQ: MRNA), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, and Tessera Therapeutics. Since its launch in 2000, Flagship has applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $212 billion in aggregate value. To date, Flagship has deployed over $2.5 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. In 2021, Flagship Pioneering was ranked 12th globally on Fortune’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies.

The Company:

Quotient Therapeutics, Inc. is a privately held, early-stage company developing a novel genomics platform and therapeutics for diseases with a large unmet need.

Position Summary:

Quotient Tx is seeking a talented and highly motivated Director of Structural Biology with relevant drug discovery experience to join our team and lead the Biomolecular Sciences group.  This is an exciting opportunity to build a new team responsible for establishing structural biology and protein science capabilities, biochemical and biophysics assays to support biology validation, hit finding campaigns and drug discovery.  The successful candidate will work closely with the Quotient Leadership Team and scientists to rapidly advance drug discovery programs to IND and early clinical studies. They will be comfortable working in and contributing to a highly dynamic and cross-functional team environment. The ideal candidate must be independent, open-minded, goal-oriented, have excellent communication skills and work in a fast-paced entrepreneurial environment.

Key Responsibilities:

• Set the scientific direction for the group and contribute to managing priorities of company’s portfolio
• Establish state-of-the art structural biology capabilities and workflows via partnership with CROs to support target validation and small molecule, antibody and other modalities drug discovery
• Establish protein expression and purification capabilities via partnership with CROs to support structural biology and biochemical/biophysical assays development
• Evaluate structures and develop structure-activity relationships in collaboration with medicinal and computational chemists as a part of the overall hit-to-lead process
• Build, lead and manage a high-performing group of talented scientists to support projects pertaining to a range of potential indications
• Effectively present and communicate research findings at internal meetings and external scientific conferences

Job Qualifications:

• Ph.D. in Structural Biology, Biophysics or a related discipline with a minimum of 10 years of relevant industry experience
• In-depth knowledge and extensive hands-on-experience with crystallography and Cryo-EM, as evidenced by a significant publication record. Experience with NMR is a plus.
• Experience in recombinant protein production from different expression systems, including construct design and optimization
• Experience with biophysical characterization assays (e.g. SPR, MST, ITC, etc.) is a plus
• Track record of delivering on project and company goals
• Ability to accommodate to rapidly changing priorities and deadlines
• Excellent communication and project leadership skills and ability to work effectively in a team setting
• Experience in managing external collaborations and CROs
• Proven track record for striving for a high level of innovation and scientific excellence

About Flagship

Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture.  Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of comp